Payment overview · 2025
General Payments
$488.49
9 reported records · 6 companies
Healthcare provider profile · identity verified
Martin Barry Mcclintock, MD
Allopathic & Osteopathic Physicians|Family Medicine · BALLWIN, MO · NPI 1427046366
Verified facts
What the public records show
CMS Open Payments records show Martin Barry Mcclintock, MD received $488.49 in general payments during 2025 across 9 reported records.
AstraZeneca Pharmaceuticals LP accounted for 57.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $282.76 | 57.9% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $125.45 | 25.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.22 | 5.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.93 | 3.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.91 | 3.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.22 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $488.49 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $143.51 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $139.25 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $125.45 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
103 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrochlorothiazide | Hydrochlorothiazide | 398 | 109 |
| Lisinopril | Lisinopril | 353 | 95 |
| Atorvastatin Calcium | Atorvastatin Calcium | 339 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 296 | 83 |
| Tamsulosin Hcl | Tamsulosin Hcl | 259 | 71 |
| Gabapentin | Gabapentin | 231 | 90 |
| Metformin Hcl | Metformin Hcl | 217 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 212 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 201 | 63 |
| Simvastatin | Simvastatin | 175 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 140 | 39 |
| Atenolol | Atenolol | 119 | 30 |
| Omeprazole | Omeprazole | 115 | 33 |
| Allopurinol | Allopurinol | 105 | 32 |
| Eliquis | Apixaban | 103 | 19 |
| Glipizide | Glipizide | 103 | 29 |
| Losartan Potassium | Losartan Potassium | 99 | 34 |
| Amitriptyline Hcl | Amitriptyline Hcl | 98 | 31 |
| Furosemide | Furosemide | 94 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 87 | 27 |
| Finasteride | Finasteride | 86 | 26 |
| Prednisone | Prednisone | 86 | 45 |
| Pioglitazone Hcl | Pioglitazone Hcl | 82 | 21 |
| Bupropion Xl | Bupropion Hcl | 80 | 24 |
| Sertraline Hcl | Sertraline Hcl | 77 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 70 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 70 | 39 |
| Buspirone Hcl | Buspirone Hcl | 69 | 32 |
| Trazodone Hcl | Trazodone Hcl | 69 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 23 |
| Glipizide Er | Glipizide | 59 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 49 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 18 |
| Montelukast Sodium | Montelukast Sodium | 46 | 14 |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Ramipril | Ramipril | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 31 | 24 |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 27 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 23 |
| Spironolactone | Spironolactone | 28 | suppressed |
| Acyclovir | Acyclovir | 27 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | 12 |
| Ozempic | Semaglutide | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Carvedilol | Carvedilol | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Potassium Chloride | Potassium Chloride | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 12 |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 15 | 11 |
| Famotidine | Famotidine | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $488.49 · 9 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, FARXIGA, GEMTESA, INGREZZA, MOUNJARO, NURTEC ODT, ZAVZPRET, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error